WO2000029436A1 - Proteine amsh et son adn complementaire - Google Patents
Proteine amsh et son adn complementaire Download PDFInfo
- Publication number
- WO2000029436A1 WO2000029436A1 PCT/JP1999/006309 JP9906309W WO0029436A1 WO 2000029436 A1 WO2000029436 A1 WO 2000029436A1 JP 9906309 W JP9906309 W JP 9906309W WO 0029436 A1 WO0029436 A1 WO 0029436A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cdna
- protein
- seq
- hamsh
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
Definitions
- This application relates to the human and mouse proteins hAMSH and mAMSH and the cDNAs encoding these proteins. More specifically, this application relates to a novel signaling molecule, AMSH, in human and mouse cells, and human and mouse genetics encoding these proteins, their cDNAs, and antibodies to proteins. Background art
- Site force-in is a protein responsible for such cell-to-cell communication, and molecules such as interleukin (IL) -1-18, colony stimulating factor (CSF), interferon (IFN), and chemokines are involved.
- IL interleukin
- CSF colony stimulating factor
- IFN interferon
- chemokines chemokines
- Cytokines bind to specific receptors on the cell membrane to generate signals in the cells, and the signaling controls the survival, proliferation, differentiation, and function of the cells. Therefore, when a series of functions of site force-in-receptor-signal transduction malfunction, immunity and hematopoietic system related to host defense are disrupted, and severe infectious disease, cancer, autoimmune disease, etc. are caused. Is done.
- the inventors of the present application have performed the isolation of the gene for the shared r-chain J that has been shared among multiple cytokines among cytokine receptors. It has greatly contributed to the elucidation of Noh.
- the r-chain is an essential receptor subunit for the expression of IL-2, IL-4, IL-7 and I-9, and the r-chain mutation is one in human X-linked severe combined immunodeficiency. It is evident that T cell early development is impaired through the dysfunction of the gene (Science, 262: 1874-1877, 1993; Int. Immunol., 6: 1451 -1454). , 1994; Science, 263: 1453-1454, 1994; Eu. Immunol., 25: 3001-3005, 1995).
- STAM STAM
- the present inventors have been elucidating some important mechanisms of the intracellular signaling pathway through the binding of the site force receptor to the cell, but the overall structure and function thereof have been elucidated. In order to elucidate this, identification of further novel molecules is indispensable. This is because the signal transduction pathway involves multiple molecules involved in a continuous and complex manner, and is thought to reach the final expression of function by constituting a so-called cascade.
- This application was made in view of the above circumstances, and interacts with the SH3 domain of the signal molecule STAM found by the inventors of the present application and is essential for downstream signal transduction from STAM. The aim is to provide novel signaling molecules that act.
- the purpose of this application is also to provide a gene of the novel molecule and its cDNA, an antibody against the novel molecule, and the like. Disclosure of the invention
- This application provides a human protein hAMSH having the amino acid sequence of SEQ ID NO: 1 as an invention for solving the above problems.
- the present application also provides a human gene encoding the above-mentioned human protein hAMSH, a cDNA of this gene, a cDNA comprising the nucleotide sequence of SEQ ID NO: 2, and a DNA fragment comprising the-part sequence of SEQ ID NO: 2.
- this application provides a recombinant vector having the above cDNA or a partial sequence thereof, and an antibody against the above human protein hAMSH.
- This application also relates to a mouse protein mAMSH having the amino acid sequence of SEQ ID NO: 3, a mouse gene encoding this mAMSH, a cDNA of this gene, a mAMSH cDNA comprising the nucleotide sequence of SEQ ID NO: 4, Provided are a DNA fragment comprising a partial sequence, a recombinant vector having the cDNA or a partial sequence thereof, and an antibody against mAMSH.
- the cDNA of the human protein hAMSH of the present invention was obtained by the far-western method using a chimeric gene of the SH3 domain of the STAM gene and glutathione S transferase (GST), which the inventors have already identified. This is the human gene cDNA isolated by screening the library. This cDNA has the nucleotide sequence of 1910 base pairs shown in SEQ ID NO: 2, and encodes the protein hAMSH whose amino acid sequence is shown in SEQ ID NO: 1.
- This protein, hAMSH was confirmed to be a novel molecule because a putative nuclear localization signal and a JAB1-like structure were confirmed in the molecule, but the corresponding molecule did not exist in the protein database.
- this protein is a novel molecule involved in cell proliferation signaling by associating with the STAM downstream of the cytoplasmic receptor, hAMSH force, '.
- AMSH-dc2 deleted from the C-terminal half of hAMSH suppresses DNA synthesis signaling after IL-2 or GM-CSF stimulation.
- the AMSH-dc2 mutant suppresses c-myc-induced signal transduction after stimulation with GM-CSF.
- the cDNA of the mouse protein mAMSH of the present invention comprises the hAMSH cDNA described above.
- Mouse gene cDNA isolated by screening a mouse cDNA library as a lobe. This cDNA has a nucleotide sequence consisting of 1384 base pairs shown in SEQ ID NO: 4, and encodes the protein mAMSH whose amino acid sequence is shown in SEQ ID NO: 2.
- the proteins hAMSH and mAMSH of the present invention can be obtained by known methods, that is, a method of isolating from human or mouse organs, cell lines, etc., or a peptide obtained by chemical synthesis based on the amino acid sequence provided by the present invention.
- RNA is prepared by in vitro transcription from a vector having the cDNA fragment of SEQ ID NO: 2, and this is used as a type III protein for in vitro translation to perform in vitro translation.
- RNA is prepared by in vitro transcription from a vector having the cDNA fragment of SEQ ID NO: 2, and this is used as a type III protein for in vitro translation to perform in vitro translation. Can be expressed.
- the translation region is recombined into an appropriate expression vector by a known method, so that a large amount of the protein encoded by the cDNA can be expressed in Escherichia coli, Bacillus subtilis, yeast, animal and plant cells, and the like.
- the protein of the present invention When the protein of the present invention is produced by expressing DNA by in vitro translation, the above cDNA or its translation region is recombined into a vector having an RNA polymerase promoter, and a heron reticulocyte lysate containing an RNA polymerase corresponding to a promoter is used.
- the protein of the present invention can be produced in vitro by adding it to an in vitro translation system such as wheat or wheat germ extract.
- the RNA polymerase promoter include T6, T3, and SP6.
- vectors containing these RNA polymerase promoters include pKA1, pCDM8, pT3 / 718, ⁇ 7 / 319, pBluescript II and the like.
- the cDNA of the present invention or a cDNA thereof may be added to an expression vector having an origin, a promoter, a ribosome binding site, a cDNA cloning site, a terminator, etc., which can be replicated in the microorganism.
- An expression vector is created by inserting a translation region, and a host cell is transformed with the expression vector. After culturing the resulting transformant, the protein encoded by the cDNA is transformed into a microorganism. Can be mass-produced within.
- a protein molecule containing an arbitrary region can be obtained by adding a start codon and a stop codon before and after an arbitrary translation region for expression. be able to.
- it can be expressed as a fusion protein with another protein, and the fusion protein can be cleaved with an appropriate protease to obtain only the target protein portion.
- the expression vector for Escherichia coli include a pUC system, pBluescript II, a pET expression system, and a pGEX expression system.
- this cDNA or its translation region is inserted into an expression vector for eukaryotic cells having a promoter, a splicing region, a poly (A) addition site, and the like.
- the protein of the present invention can be produced in animal cells by introducing the recombinant vector into eukaryotic cells.
- expression vectors include pKA1, pCDM8, pSVK3, pMSG, pSV, pBK-CMV, pBK-RSV, EBV vector, pRS, and pYES2.
- mammalian cultured cells such as monkey kidney cells C ⁇ S7, Chinese hamster ovary cells CHO, budding yeast, fission yeast, silkworm cells, African egg cells and the like are generally used. Any eukaryotic cell that can express the protein may be used.
- known methods such as an electroporation method, a calcium phosphate method, a ribosome method, and a DAE dextran method can be used.
- a known protein After expressing the protein of the present invention in a microorganism or eukaryotic cell, a known protein can be isolated and purified from the culture by a combination of known separation procedures. For example, treatment with denaturing agents such as urea or surfactants, sonication, enzyme digestion, salting-out / solvent precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing Ion chromatography, hydrophobic chromatography, affinity chromatography, reverse phase chromatography and the like.
- denaturing agents such as urea or surfactants, sonication, enzyme digestion, salting-out / solvent precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing Ion chromatography, hydrophobic chromatography, affinity chromatography, reverse phase chromatography and the like.
- the proteins hAMSH and mAMSH of the present invention include peptide fragments (5 or more amino acid residues) containing any partial amino acid sequence of the amino acid sequences represented by SEQ ID NOS: 1 and 3, respectively. These peptide fragments can be used as antigens for producing antibodies.
- the protein of the present invention also includes a fusion protein with any other protein.
- the gene of the present invention is a human gene encoding the above-mentioned protein.
- an existing genomic library can be used. Rally.
- the cDNA of the present invention is obtained by screening cDNA libraries derived from human cells or mouse cells by known colony or plaque hybridization using oligonucleotide probes synthesized based on the nucleotide sequences of SEQ ID NOs: 2 and 4, respectively. Can be obtained. In addition, an oligonucleotide that hybridizes to both ends of the cDNA fragment is synthesized, and using this as a primer, the cDNA fragment of the present invention is obtained by RT-PCR from mRNA isolated from human cells or mouse cells. Can also be prepared.
- the cDNA of SEQ ID NO: 2 or 4 in which one or more nucleotides have been added, deleted and / or substituted by other nucleotides are also included in the cDNA of the present invention.
- proteins having one or more amino acids added, deleted, and substituted with amino acids or other amino acids resulting from these changes are also proteins having the amino acid sequence represented by SEQ ID NO: 1 or 3. As long as it has activity, it is included in the protein of the present invention.
- the DNA fragment of the present invention includes a cDNA fragment (10 bp or more) containing any partial base sequence of the base sequence represented by SEQ ID NO: 2 or 4. DNA fragments consisting of the sense strand and the antisense strand also fall into this range. These DNA fragments can be used as probes for gene diagnosis.
- An antibody against the protein of the present invention can be obtained as a polypolyclonal antibody or a monoclonal antibody by a known method using the protein itself or a partial peptide thereof as an antigen.
- a part of the hAMSH cDNA (383-550 of SEQ ID NO: 2, corresponding to amino acid numbers 125-180 of SEQ ID NO: 1) was amplified by PCR and inserted into a GST fusion protein expression vector.
- This vector was transformed into host E. coli by transformation, and the transformant was stimulated with IPTG to induce the expression of the GST fusion protein.
- Glutathione kara The purified GST fusion protein was obtained by purification. Rabbits were immunized using the GST fusion protein as an antigen to obtain antisera.
- the present invention provides a novel signaling molecule involved in the site-in signaling pathway and a material for genetically manipulating the same. These molecules and genetically engineered materials are useful for the development of methods, drugs, etc. for diagnosis and treatment of human diseases caused by impaired function of cytokine signaling pathways such as severe infectious diseases, cancer, and autoimmune diseases. It is.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99972223A EP1130029B1 (en) | 1998-11-12 | 1999-11-12 | Protein amsh and cdna thereof |
DE69940319T DE69940319D1 (de) | 1998-11-12 | 1999-11-12 | Amsh protein und dessen cdns |
CA002351618A CA2351618C (en) | 1998-11-12 | 1999-11-12 | Protein amsh and cdna thereof |
AU11786/00A AU773717B2 (en) | 1998-11-12 | 1999-11-12 | Protein AMSH and CDNA thereof |
US09/831,452 US7423134B1 (en) | 1998-11-12 | 1999-11-12 | Protein AMSH and cDNA thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/322674 | 1998-11-12 | ||
JP32267498A JP3764286B2 (ja) | 1998-11-12 | 1998-11-12 | タンパク質AMSHとそのcDNA |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/831,452 A-371-Of-International US7423134B1 (en) | 1998-11-12 | 1999-11-12 | Protein AMSH and cDNA thereof |
US10/671,572 Division US6838551B2 (en) | 1998-11-12 | 2003-09-29 | Protein AMSH and cDNA thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000029436A1 true WO2000029436A1 (fr) | 2000-05-25 |
Family
ID=18146351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/006309 WO2000029436A1 (fr) | 1998-11-12 | 1999-11-12 | Proteine amsh et son adn complementaire |
Country Status (7)
Country | Link |
---|---|
US (1) | US7423134B1 (ja) |
EP (1) | EP1130029B1 (ja) |
JP (1) | JP3764286B2 (ja) |
AU (1) | AU773717B2 (ja) |
CA (1) | CA2351618C (ja) |
DE (1) | DE69940319D1 (ja) |
WO (1) | WO2000029436A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055536A2 (en) * | 2001-01-12 | 2002-07-18 | California Institute Of Technology | Regulation of target protein activity through modifier proteins |
WO2002102144A1 (en) * | 2001-06-18 | 2002-12-27 | Japan Science And Technology Corporation | Cell deah-inducible model nonhuman animal |
US7279317B2 (en) | 2001-01-12 | 2007-10-09 | California Institute Of Technology | Modulation of COP9 signalsome isopeptidase activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6468546B1 (en) * | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
WO2001021794A2 (en) * | 1999-09-20 | 2001-03-29 | Ludwig Institute For Cancer Research | Smad associating polypeptides |
US20030073623A1 (en) * | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
-
1998
- 1998-11-12 JP JP32267498A patent/JP3764286B2/ja not_active Expired - Fee Related
-
1999
- 1999-11-12 US US09/831,452 patent/US7423134B1/en not_active Expired - Fee Related
- 1999-11-12 EP EP99972223A patent/EP1130029B1/en not_active Expired - Lifetime
- 1999-11-12 DE DE69940319T patent/DE69940319D1/de not_active Expired - Lifetime
- 1999-11-12 CA CA002351618A patent/CA2351618C/en not_active Expired - Fee Related
- 1999-11-12 WO PCT/JP1999/006309 patent/WO2000029436A1/ja active IP Right Grant
- 1999-11-12 AU AU11786/00A patent/AU773717B2/en not_active Ceased
Non-Patent Citations (4)
Title |
---|
KAZUO SUGAMURA ET AL.: "Possible involvement of a novel STAM-associated molecule "AMSH" in intracellular signal transduction mediated by cytokines", J. BIOL. CHEM.,, vol. 274, no. 27, July 1999 (1999-07-01), pages 19129 - 19135, XP000907141 * |
MEREDITH A. WENTLAND ET AL.: ""A Double" method for improved shotgun library construction", ANALYTICAL BIOCHEMISTRY,, vol. 236, no. 1, 1996, pages 107 - 113, XP002927605 * |
SUGAMURA K. ET AL.: "STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction", IMMUNITY,, vol. 6, no. 4, 1997, pages 449 - 457, XP002927608 * |
WEI YU ET AL.: "Large-scale concatenation cDNA sequencing", GENOME RESEARCH,, vol. 7, no. 4, 1997, pages 353 - 358, XP002927606 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055536A2 (en) * | 2001-01-12 | 2002-07-18 | California Institute Of Technology | Regulation of target protein activity through modifier proteins |
WO2002055536A3 (en) * | 2001-01-12 | 2003-10-23 | California Inst Of Techn | Regulation of target protein activity through modifier proteins |
EP1385942A2 (en) * | 2001-01-12 | 2004-02-04 | California Institute of Technology | Regulation of target protein activity through modifier proteins |
EP1385942A4 (en) * | 2001-01-12 | 2004-08-25 | California Inst Of Techn | REGULATION OF THE ACTIVITY OF TARGET PROTEINS BY MODIFYING PROTEINS |
US6846663B2 (en) | 2001-01-12 | 2005-01-25 | California Institute Of Technology | Regulation of target protein activity through modifier proteins |
US7279317B2 (en) | 2001-01-12 | 2007-10-09 | California Institute Of Technology | Modulation of COP9 signalsome isopeptidase activity |
US7291494B2 (en) | 2001-01-12 | 2007-11-06 | California Institute Of Technology | Regulation of target protein activity through modifier proteins |
WO2002102144A1 (en) * | 2001-06-18 | 2002-12-27 | Japan Science And Technology Corporation | Cell deah-inducible model nonhuman animal |
Also Published As
Publication number | Publication date |
---|---|
EP1130029A4 (en) | 2005-03-09 |
EP1130029A1 (en) | 2001-09-05 |
CA2351618A1 (en) | 2000-05-25 |
JP3764286B2 (ja) | 2006-04-05 |
JP2000139469A (ja) | 2000-05-23 |
AU1178600A (en) | 2000-06-05 |
AU773717B2 (en) | 2004-06-03 |
DE69940319D1 (de) | 2009-03-05 |
US7423134B1 (en) | 2008-09-09 |
EP1130029B1 (en) | 2009-01-14 |
CA2351618C (en) | 2008-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1243650B1 (en) | Process for constructing a cDNA library | |
Bunz et al. | cDNAs encoding the large subunit of human replication factor C. | |
JPH06502176A (ja) | 新しいオンコフェータル遺伝子、そのための遺伝子生成物およびその利用法 | |
Zimmermann et al. | Native versus recombinant high-mobility group B1 proteins: functional activity in vitro | |
US7226997B2 (en) | Mast cell-specific signal transducer and cDNA thereof | |
WO2000029436A1 (fr) | Proteine amsh et son adn complementaire | |
US6838551B2 (en) | Protein AMSH and cDNA thereof | |
WO2000023586A1 (fr) | PROTEINE HUMAINE Grf40 ET ADNc DE CETTE PROTEINE | |
WO2000023468A1 (fr) | Proteines humaines stam2a et stam2b et adnc codant ces molecules | |
EP0780472A2 (en) | Stress proteins | |
US5665588A (en) | DNA encoding natural killer lytic associated protein | |
JP2007222001A (ja) | 疎水性ドメインを有するヒトタンパク質及びそれをコードするdna | |
US20040229237A1 (en) | Mast cell-specific signal transducer and cDNA thereof | |
WO2001096552A1 (fr) | Canaux sodiques scn1a et scn3a | |
JP2003259871A (ja) | 脳特異的発現を示す分泌タンパク質creg2とその利用 | |
JPH11507833A (ja) | 新規免疫調節タンパク質 lst−1 | |
JPH09182588A (ja) | クラスリン結合タンパク遺伝子 | |
JPH11332576A (ja) | ヒト蛋白質hUbc12とこの蛋白質をコードする cDNA | |
WO2005040380A1 (ja) | げっ歯類動物の免疫応答調節蛋白質 | |
JPH1132774A (ja) | ヒト26sプロテアソーム構成成分蛋白質及びそれをコードするdna | |
JP2001161367A (ja) | ヒト蛋白質とcDNA[2] | |
JP2000201684A (ja) | ナトリウムチャンネルscn8a | |
JP2001224374A (ja) | ヒト蛋白質とcDNA[6] | |
JPH09294588A (ja) | ヒトrch1関連蛋白遺伝子 | |
CN1394959A (zh) | 人环指蛋白酶编码序列、其制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 11786 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2351618 Country of ref document: CA Ref country code: CA Ref document number: 2351618 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999972223 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09831452 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11786/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999972223 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 11786/00 Country of ref document: AU |